In clinical practice, neurologists should consider measuring Lp(a) levels in patients with cryptogenic stroke, ESUS, recurrent ischemic stroke despite optimal risk factor control, early-onset stroke, intracranial or extracranial atherosclerosis, and concomitant coronary artery disease. This evidence concerns the gene LPA and Stroke.